Home / Business / Mazor Robotics Reports Orders for Six Renaissance Systems During the Fourth Quarter of 2014
Photo by Michael Dorausch, michaeldorausch.com; License: https://creativecommons.org/licenses/by-sa/2.0/legalcode

Mazor Robotics Reports Orders for Six Renaissance Systems During the Fourth Quarter of 2014 מזור רובוטיקה מדווחת על הזמנות לשש מערכות רנסנס במהלך הרבעון הרביעי של 2014

  • Mazor Robotics Ltd., developer of robotic surgical guidance systems, announced that the company received six orders for Renaissance spine surgery systems in fourth quarter 2014.
  • Completion of these agreements did not occur by the end of the year and as a result will impact fourth quarter revenue.
  • The company has provided preliminary fourth quarter and full year revenue due to upcoming meetings with investors. Complete reports will be available Feb 18.

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQ GM:MZOR), a developer of innovative guidance systems and complementary products, announced today that it received orders for and delivered six Renaissance systems, two in the U.S. and four internationally, in the fourth quarter ended December 31, 2014. The Company ended 2014 with 83 Renaissance systems globally, with 46 in the U.S., the Company’s primary growth market, compared with 63 and 34 systems in 2013, respectively.

Based on currently available operating and financial information, the Company expects to report revenue of approximately $5.7 million for the fourth quarter ended December 31, 2014. For the full year, Mazor expects to report revenue of approximately $21 million compared to revenue of $20 million in 2013. The anticipated results in this press release are based on management’s preliminary unaudited analysis of financial results for the quarter and year ended December 31, 2014.

“While we were in active negotiations to complete the sale of one or more Renaissance systems with several U.S. hospitals, the completion of these agreements did not occur by the end of the year and, as a result, our fourth quarter revenue will be impacted,” said Ori Hadomi, Mazor’s Chief Executive Officer. “Our organization is continuing to pursue these agreements as we enter 2015. We are still at the very early stage of developing the robotic spine surgery market and continue to experience a high level of interest and sales activity in the Renaissance system in our key markets. We remain confident that with strong data supporting the clinical and economic benefits of the Renaissance system and continued sales and marketing efforts we will expand our presence in these markets over the longer term.”

The Company has provided preliminary financial results for the fourth quarter and full year due to upcoming meetings with investors in mid-January. The Company intends to maintain its policy of not providing an outlook on its future financial results and is not obligated to comment on expected results in the future. The Company currently intends to report its complete financial results for the fourth quarter and full year ended December 31, 2014 on February 18, 2015.

About Mazor

Mazor Robotics is dedicated to the development and marketing of innovative surgical guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance®, is a state-of-the-art surgical guidance system that enables surgeons to conduct spine and brain surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 60,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding our fourth quarter and full year revenue expectations, pursuing in 2015 agreements we negotiated in 2014, expanding our presence in the U.S. and international markets over the longer term, our policy of not providing an outlook on our future financial results, , the time for reporting of our fourth quarter results, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 9, 2014 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

U.S. Contacts: EVC Group
Investors:
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Robert Jones, 646-201-5447
bjones@evcgroup.com
or
Media:
Dave Schemelia, 646-201-5431
dave@evcgroup.com

Comments

comments

About bio972